SCHEMBL2222880

SCHEMBL2222880

Cc1ccc(-c2nc3ccc(C)cn3c2Cn2nc3ccccc3n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.57
GABRA1 P14867 3/20 0.54
GABRB2 P47870 3/20 0.54
KDM4E B2RXH2 2/20 0.54
LMNA P02545 1/20 0.54
ALB P02768 1/20 0.54
CYP3A4 P08684 1/20 0.54
CHRM1 P11229 1/20 0.54
HPGD P15428 1/20 0.54
GABRB1 P18505 1/20 0.54
GABRG2 P18507 1/20 0.54
GABRB3 P28472 1/20 0.54
GABRA3 P34903 1/20 0.54
ADRA1A P35348 1/20 0.54
OPRK1 P41145 1/20 0.54
HTR2B P41595 1/20 0.54
GABRA2 P47869 1/20 0.54
KCNH2 Q12809 1/20 0.54
HSD17B10 Q99714 1/20 0.54
SLC2A1 P11166 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2230114 0.84 SMN1; SMN2 (0.52) SMN1; SMN2GABRA1GABRB2KDM4ELMNA
SCHEMBL2230797 0.81 PKM (0.60) SMN1; SMN2GABRA1GABRB2KDM4ELMNA
SCHEMBL2228762 0.81 GABRA1 (0.53) SMN1; SMN2GABRA1GABRB2KDM4ELMNA
SCHEMBL1433233 0.79 SLC2A1 (0.60) GABRB2KDM4EGABRA2SLC2A1ALDH1A1
SCHEMBL2275461 0.78 SMN1; SMN2 (0.56) SMN1; SMN2GABRA1GABRB2KDM4ELMNA
SCHEMBL2196219 0.78 SLC2A3 (0.54) GABRA1GABRB2KDM4ESLC2A1ALDH1A1
SCHEMBL1430476 0.77 GABRA1 (0.61) SMN1; SMN2GABRA1GABRB2KDM4ELMNA
SCHEMBL4253068 0.77 GABRA1 (0.61) SMN1; SMN2GABRA1GABRB2KDM4ELMNA
SCHEMBL29621620 0.77 GABRA1 (0.61) SMN1; SMN2GABRA1GABRB2KDM4ELMNA
SCHEMBL1691670 0.77 GABRA1 (0.65) SMN1; SMN2GABRA1GABRB2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD SMN1; SMN2 593/4885GABRA1 817/4885GABRB2 1166/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD SMN1; SMN2 593/4885GABRA1 817/4885GABRB2 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.